菲律宾宿务单剂次大规模登革热疫苗接种的效果:一项5年病例对照研究的最终结果
菲律宾宿务省2017年中期为9至14岁儿童启动CYD-TDV(Dengvaxia,赛诺菲)大规模接种,仅接种一剂后即中止。本研究为2018年2月15日至2023年2月28日开展的病例对照研究,纳入584例住院病毒学确诊登革热(VCD)病例和1168名同性别同年龄组社区对照。结果显示,接种一剂CYD-TDV对住院VCD的总体保护为21%(95%CI,-7至41%;p=0.1129),对较重临床表现(登革热伴预警征和重症登革热)的保护为31%(95%CI,6至49%;p<0.0001)。结论认为单剂次CYD-TDV对较重临床表现登革热提供延长保护;研究局限为缺乏接种前基线登革热血清状态,但该队列绝大多数可能为登革热血清阳性。
要点
- 单剂次CYD-TDV对住院VCD总体保护21%(95%CI -7至41%;p=0.1129),未达统计学显著。
- 单剂次CYD-TDV对登革热伴预警征和重症登革热的保护为31%(95%CI 6至49%;p<0.0001)。
- 584例VCD中397例(67.8%)为登革热伴预警征,8例(1.4%)重症登革热,1例(0.2%)死亡。
核心结论
- 单剂次CYD-TDV对较重临床表现登革热提供延长保护。
- 研究局限为缺乏接种前基线登革热血清状态,但该队列绝大多数可能为登革热血清阳性。
研究设计与样本
- 2018年2月15日至2023年2月28日在宿务省开展的病例对照研究。
- 纳入2017年中期符合登革热大规模接种条件、随后因疑似登革热入住四所参与公立医院中任一家的宿务儿童。
- 采集血样行登革热RT-PCR,获取临床和社会人口学信息。
- 住院VCD患儿随访至出院,按WHO 2009标准分类为登革热、登革热伴预警征和重症登革热。
- 比较VCD病例与同性别同年龄组社区对照的接种状态以估计疫苗保护水平。
主要发现
- 分析纳入584例VCD病例和1168名对照。
- 584例中397例(67.8%)为登革热伴预警征,8例(1.4%)为重症登革热,1例(0.2%)死亡。
- 四种登革病毒血清型均检出,血清型3最常见(287/584,49.1%)。
- 接种一剂CYD-TDV对住院VCD的总体保护为21%(95%CI,-7至41%;p=0.1129)。
- 接种一剂CYD-TDV对较重临床表现(登革热伴预警征和重症登革热)的保护为31%(95%CI,6至49%;p<0.0001)。
局限性
- 研究缺乏参与者接种前基线登革热血清状态。
- 该队列绝大多数可能为登革热血清阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In mid-2017, the Philippine Department of Health launched a vaccination program of nine- to fourteen-year-old children using CYD-TDV (Dengvaxia, Sanofi) in Cebu province. The vaccination program was discontinued after only one dose was given. Until 2020, the interim vaccine effectiveness against hospitalized virologically confirmed dengue (VCD) and dengue with warning signs was 26 % and 51 %, respectively. In this report, we assess vaccine protection through February 2023. METHODS: From 15 February 2018 to 28 February 2023, we conducted a case-control study in Cebu province. Children residing in Cebu who were eligible to participate in the dengue mass vaccination in mid-2017 and subsequently admitted to any of four participating public hospitals with suspected dengue were enrolled. A blood sample was collected for dengue RT-PCR and clinical and socio-demographic information were obtained. Children hospitalized with VCD were followed until discharge and their illness classified according to WHO 2009 criteria as dengue, dengue with warning signs and severe dengue. To estimate the level of vaccine protection, vaccination status was compared between VCD cases and neighborhood controls of the same sex and age-group. FINDINGS: We included 584 VCD cases and 1168 controls in the analysis. Of the 584 cases, 397 (67·8 %) presented as dengue with warning sign (DWS), 8 (1·4 %) had severe dengue, and 1 (0·2 %) died. All four dengue virus serotypes were detected, but serotype 3 was the most common (287/584 or 49·1 %). Receipt of one dose of CYD-TDV was associated with 21 % (95 % CI, -7 to 41 %; p = 0·1129) overall protection against hospitalized VCD and 31 % (95 % CI, 6 to 49 %; p < 0·0001) protection against more severe presentations of dengue (dengue with warning signs and severe dengue). CONCLUSION: A single dose of CYD-TDV conferred extended protection against more severe presentations of dengue. The study is limited by an absence of baseline dengue serostatus of the participants prior to vaccination but a large majority in this this cohort were likely dengue seropositive.
引用
- Agrupis KA, Crisostomo MV, Daag JV, et al. Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: Final results of a 5-year case-control study. Vaccine. 2025. PMID: 40279922. doi:10.1016/j.vaccine.2025.127142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。